Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05529966 · ClinicalTrials.gov registry record · NA
Comparing NGENUITY vs Conventional Microscope in a New Hydrus User
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT05529966: Completed NA study, sponsored by Stanford University.
NCT05529966 is a NA study that has completed, run by Stanford University. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05529966, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
To compare the potential efficiency and educational value of using NGENUITY (3D camera system, FDA approved for this indication) vs the conventional microscope for Hydrus microstent placement by new users.
Interventions
- DEVICE NGENUITY
- DEVICE Conventional microscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2024-03-22 |
| Phase | NA |
What the finished NCT05529966 record still lists
NCT05529966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which NGENUITY is the first listed.
NCT05529966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05529966 about?
NCT05529966 is a clinical study titled "Comparing NGENUITY vs Conventional Microscope in a New Hydrus User". To compare the potential efficiency and educational value of using NGENUITY (3D camera system, FDA approved for this indication) vs the conventional microscope for Hydrus microstent placement by new users.
What is the current status of trial NCT05529966?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2023-02-13. Estimated completion is 2024-03-22.
What interventions are being tested in trial NCT05529966?
The interventions under investigation include: NGENUITY (DEVICE), Conventional microscope (DEVICE).
Who is sponsoring clinical trial NCT05529966?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05529966's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI